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Background: Ovarian low-grade serous carcinoma (LGSC) has fewer mutations than ovarian high-grade serous
carcinoma (HGSC) and a less aggressive clinical course. However, an overwhelming majority of LGSC patients do not
respond to conventional chemotherapy resulting in a poor long-term prognosis comparable to women diagnosed
with HGSC. KRAS and BRAF mutations are common in LGSC, leading to clinical trials targeting the MAPK pathway.
We assessed the stability of targetable somatic mutations over space and/or time in LGSC, with a view to inform
stratified treatment strategies and clinical trial design.
Methods: Eleven LGSC cases with primary and recurrent paired samples were identified (stage IIB-IV). Tumor DNA was
isolated from 1–4 formalin-fixed paraffin-embedded tumor blocks from both the primary and recurrence (n = 37 tumor
and n = 7 normal samples). Mutational analysis was performed using the Ion Torrent AmpliSeqTM Cancer Panel, with
targeted validation using Fluidigm-MiSeq, Sanger sequencing and/or Raindance Raindrop digital PCR.
Results: KRAS (3/11), BRAF (2/11) and/or NRAS (1/11) mutations were identified in five unique cases. A novel,
non-synonymous mutation in SMAD4 was observed in one case. No somatic mutations were detected in the
remaining six cases. In two cases with a single matched primary and recurrent sample, two KRAS hotspot mutations
(G12V, G12R) were both stable over time. In three cases with multiple samplings from both the primary and
recurrent surgery some mutations (NRAS Q61R, BRAF V600E, SMAD4 R361G) were stable across all samples, while
others (KRAS G12V, BRAF G469V) were unstable.
Conclusions: Overall, the majority of cases with detectable somatic mutations showed mutational stability over space
and time while one of five cases showed both temporal and spatial mutational instability in presumed drivers of
disease. Investigation of additional cases is required to confirm whether mutational heterogeneity in a minority of
LGSC is a general phenomenon that should be factored into the design of clinical trials and stratified treatment for
this patient population.
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In comparison to the more commonly occurring high-grade
serous carcinomas (HGSC), ovarian low-grade serous
carcinomas (LGSC) are characterized by a younger age at
onset, lower mitotic rate and longer median overall survival* Correspondence: dhuntsma@bccancer.bc.ca
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unless otherwise stated.[1-6]. Whereas the vast majority (80%) of patients with
HGSC are responsive to platinum-based chemotherapy,
patients with LGSC are highly resistant to treatment in the
neoadjuvant, adjuvant and recurrent setting, with response
rates of 4-5% [1,7,8]. Women diagnosed with LGSC
typically experience multiple recurrences over a protracted
clinical course before ultimately dying of their disease, with
an associated 10-year survival rate of <50% [2]. This
suggests that despite having a less aggressive clinical
course, women with LGSC have a poor long-term prognosis
similar to HGSC patients; this is highlighted by a recenthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and HGSC patients with measurable residual disease after
adjusting for additional variables [9].
In an effort to identify potential molecular targets,
limited mutational studies in primary or recurrent
LGSC samples have revealed an overall low mutation
frequency, with exome sequencing by Jones et al.
showing an average of 10 validated somatic mutations
(or 7.5 somatic non-synonymous or splice site mutations)
per tumor [10]. The mitogen-activated kinase (MAPK)
pathway is most frequently mutated [11], with 19-35% of
cases containing a KRAS mutation and 2-33% containing
a BRAF mutation [3,10,12-14]. KRAS and BRAF muta-
tions are also frequently detected in serous borderline
tumors (SBT), the histologic precursor to invasive LGSC
[5,6,11,15-17].
The prevalence of KRAS/BRAF mutations in LGSC
has resulted in clinical trials of inhibitors of MAP kinase
kinase (MEK1/2), which lies immediately downstream of
BRAF and upstream of ERK1/2 in the MAPK pathway
[18,19]. Previous studies have reported profound growth
inhibition and apoptosis in ovarian cancer cells with
mutated but not wildtype KRAS or BRAF upon treatment
with CI-1040 [20] in tissue culture and xenograft studies
[19,21], suggesting that mutation status predicts sensitivity
to MEK inhibition. A recent phase II study of selumetinib,
another small molecular inhibitor of MEK1/2, in women
with recurrent ovarian/peritoneal LGSC has shown an
objective 15% response rate despite heavy pre-treatment;
however patient response does not appear to be correlated
with KRAS/BRAF mutation status [18]. The mutation
status of the patients in this trial was based solely on
a single sample of LGSC; most were obtained from
the primary tumor and a small percentage were obtained
from the recurrent tumor. In this study we aimed to assess
the stability of targetable mutations over space and/or
time by targeted sequence analysis of one or more tumor
samples from both the primary and recurrence, to inform
future clinical trial design. Herein we report our findings
of mutational stability in the majority of cases, as well as
remarkable instability in one case of ovarian LGSC, in
presumed drivers of disease KRAS and BRAF. If validated
in more cases this could impact clinical trial design for
this patient population in the future.
Methods
Study cases
A total of 11 cases of LGSC with matched primary and re-
current samples available were identified from the University
Health Network in Toronto, Ontario (“UHN”, n = 3), MD
Anderson Cancer Center in Houston, Texas (“MDACC”,
n = 3) and the BC Cancer Agency in Vancouver, British
Columbia (“BCCA”, n = 5). The stage breakdown included:
IIB (n = 1), IIIB (n = 3), IIIC (n = 6) and IV (n = 1). Researchethics approval was obtained from each site (UBC BCCA
Research Ethics Board, University Health Network Research
Ethics Board and The University of Texas MD Anderson
Cancer Center Institutional Review Board). All patients
provided written informed consent to have their tissue
samples used for research purposes, including genomic
studies. Written informed consent was obtained from
every patient for publication of the specific clinical details
included within this research article and any accompany-
ing images. However, potentially identifying information
such as date of diagnosis have been removed to protect
privacy. Upon inclusion in the study, all formalin-fixed
paraffin-embedded (FFPE) sections chosen for sequence
analysis were subjected to secondary pathologic review
(B.G.). Two of eleven cases originally presented as a SBT,
and recurred as invasive LGSC. Nine patients received
adjuvant treatment following diagnosis, including six treated
with combined carboplatin/paclitaxel.
A total of 37 tumor samples (from either FFPE blocks
[BCCA] or unstained sections [MDACC/UHN]) were
included for analysis. At least one sampling from both the
primary and recurrent setting were included for each case,
with H&E-guided macrodissection used to isolate tumor
from adjacent stromal cells. Tumor cellularity achieved
following macrodissection was estimated at a median of
80% (range 50-95%) and was comparable among samples
obtained from the same case. Normal samples were
available for 7 cases (6 matched normal tissue, 1 buffy
coat). We were also able to obtain a fresh blood sample
from one BCCA study patient for extraction of circulating
tumor DNA (“ctDNA”). Summary information for all
study cases is included in Table 1, with more detailed
information on tumor sites and normal samples used in
Additional file 1 and case images in Additional files 2, 3, 4,
5, 6, 7, 8, 9, 10, 11 and 12.
DNA extraction
Tumor and normal DNA was extracted from FFPE
blocks/unstained sections (see Additional file 13 for
supplemental methods). For extraction of ctDNA, whole
blood was collected in EDTA tubes then centrifuged at
2,500 rpm for 15 min. Plasma was then stored at -80C in
1-2 mL aliquots, followed by extraction of plasma ctDNA
using the Qiagen Circulating Nucleic Acid kit as per
manufacturer’s protocol. ctDNA was then eluted in 30uL
of Buffer AVE.
Ion torrent AmpliSeq cancer hotspot sequencing
The Ion Torrent AmpliSeqTM Cancer Hotspot Panel
Version 1 (Life Technologies, Grand Island/NY/USA)
[22] was used to prepare sequencing libraries from all
tumor DNA, normal DNA and plasma ctDNA as per
manufacturer’s protocols (see Additional file 13 for meth-
odological details and Additional file 14 for a comprehensive
Table 1 Summary of study cases








LGSC-2 UHN 57 2 IIIC 2-P* Carboplatin/paclitaxel 2-R (46 mo) 86 mo / AWD
LGSC-3 UHN 51 2 IIIC 3-P* Carboplatin/paclitaxel 3-R (17 mo) 19 mo / AWD
LGSC-4 UHN 66 3 IIIB 4-P Carboplatin 4-R1 (25 mo), 4-R2 (45 mo) 60 mo / DOD
LGSC-5 MDACC 51 2 IIIC 5-P Carboplatin/paclitaxel, letrozole 5-R (37 mo) 53 mo / DOD
LGSC-6 MDACC 41 2 IIIC 6-P Carboplatin/paclitaxel 6-R (24 mo) 87 mo / DOD
LGSC-8 MDACC 33 2 IIIC 8-P Cisplatin/cyclophos-phamide 8-R (7 mo) 12 mo / DOD
LGSC-9** BCCA 51 6 IIIB 9-P1, P2, P3* No treatment 9-R1, R2, R3 (100 mo) 141 mo / DOD
LGSC-10 BCCA 57 8 IV 10-P1, P2, P3, P4* Carboplatin/paclitaxel,
radiation
10-R1, R2, R3, R4 (45 mo) 62 mo / DOD
LGSC-11** BCCA 62 2 IIIC 11-P* No treatment 11-R (156 mo) 180 mo / DOD
LGSC-12 BCCA 57 6 IIB 12-P1, P2, P3, P4* Etoposide, tamoxifen,
anastrozole
12-R1, R2 (18 mo) 53 mo / DOD




*normal sample also available; **initial diagnosis of SBT; ***time in months since diagnosis.
Abbreviations: AWD = alive with disease, DOD = dead of disease.
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panel). A list of predicted variants was generated for each
sample using the built-in AmpliSeq Cancer Variant Caller
following each run. Upon completion of all samples,
we performed a separate bioinformatics analysis. Sequence
reads were aligned to the human reference sequence
(UCSC hg19) using the BWA SW algorithm (v0.6.1) [23]
with default parameters. Single nucleotide variants (SNV)
were called using mutationSeq [24], a feature-based
method to filter out technical artifacts. We used a variant
probability threshold of 0.5 to nominate SNVs. Variants
predicted in the pooled normal data were considered as
germline mutations and were removed.
Variants were selected for targeted validation by MiSeq
in all samples according to the following selection criteria:
[1] either somatic (variant not found in corresponding
normal sample if available) or predicted somatic (for cases
with no corresponding normal – variant not found in
dbSNP or in normal samples from other cases), [2]
non-synonymous and [3] predicted functional impact
according to MutationAssessor [25], a method to predict
the functional impact of missense mutations on protein
products based on evolutionary conservation of amino
acid residues in multi-sequence alignment of homologous
protein sequences.
Fluidigm-MiSeq targeted sequencing validation
Variants identified by Ion Torrent AmpliSeq sequencing
results were verified by validation sequencing using the
Fluidigm 48X48 AccessArray amplification (Fluidigm, San
Francisco/CA/USA) coupled with the Illumina MiSeq
personal sequencer (Illumina Inc, San Diego/CA/USA)(see Additional file 13). Sequence reads were aligned using
the mem algorithm of BWA v0.7.4 [26] to a reference
database containing only the targeted loci. We inferred
the presence/absence of the targeted variants using a
Binomial exact test. In the context of this analysis, a
somatic mutation was considered to be “validated” if: [1]
both tumor and normal data had a minimum of 50 reads
covering the targeted position, [2] the Binomial exact
test result (Benjamini Hochberg adjusted p-value) for
the tumor was <0.01, [3] the Binomial exact test result
(Benjamini Hochberg adjusted p-value) for the normal
was > =0.01, and [4] the proportion of reads indicating the
variant in the tumor was ≥5%. For the cases without a
normal control, the validated variants also shown in the
pooled normal data were considered as germline mutations
and were removed. All mutations were visually confirmed
using the Integrative Genomics Viewer (Broad Institute,
Cambridge/MA/USA).
Sanger sequencing
Sanger sequencing was used to confirm select high allelic
fraction mutations, using methods previously described
[27]. Primer sequences are listed in Additional file 15.
Raindance raindrop digital PCR assay
Custom TaqMan SNP Genotyping assays (Life Technologies,
CA/USA) were used as primer/probes (40X) to confirm
low allelic fraction mutations using the Raindance
Raindrop digital PCR assay (Raindance, Billerica/MA/USA).
Sequences for primers are shown in Additional file 16.
Digital PCR assays were performed as per manufacturer’s
protocols (see Additional file 13).
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Only those mutations that were detected by at least two
independent technologies were considered “true positives”
and were included in intra-patient comparisons.
Results
Overall mutational landscape of LGSC study cases
Following initial screening by Ion Torrent and validation
by MiSeq, Sanger and/or digital PCR, very few “true
positive” mutations were observed overall, with only 7
mutations detected among 5 of 11 cases. No somatic
mutations were observed in cases LGSC-2, LGSC-4,
LGSC-5 and LGSC-13, whereas predicted mutations in
cases LGSC-6 and LGSC-8 were only detected by one of
the sequencing platforms used. True positives included
KRAS mutations in 3 cases (n = 2 G12V and n = 1
G12R), BRAF mutations in 2 cases (n = 1 V600E and
n = 1 G469V), and NRAS (Q61R) and SMAD4 (R361G)
mutations in one case each. The average allelic fraction of
each of these mutations in individual samples as deter-
mined by Ion Torrent and MiSeq is shown in Figure 1
(see Additional file 17 and Additional file 18 for data from
each platform). Mutational patterns over time/space will
be discussed for individual cases in the following sections.
Mutational stability over time
Two cases with one primary and recurrent sample each
(LGSC-3 and LGSC-11) were used to assess temporal
stability of confirmed somatic mutations (see Figure 2A-B
for overview of clinical course).
LGSC-3 is from a 51 year old patient diagnosed
with bilateral ovarian LGSC with extensive extra-ovarian
involvement, stage IIIC (described in Additional file 1).
This patient received adjuvant carboplatin/paclitaxel prior
to disease recurrence 17 months after primary diagnosis.






Figure 1 Average allele fraction of confirmed somatic mutations by ion
in a specific tumor sample (listed at bottom) is indicated by a colored box in
average allele fraction as detected by Ion Torrent and MiSeq. Corresponding
described mutations.was alive with disease. Sequencing analysis discovered a
KRAS hotspot mutation (chr12:25,398,284C >A, G12V) at
a similar allelic fraction of ~50% (range 48-53%) in
the primary and recurrent samples, suggesting that this
was a stable feature in this tumor (see Additional file 19
for confirmation by Sanger).
LGSC-11 is from a 62 year old patient diagnosed with
stage IIIC SBT of the left ovary, with ovarian surface
involvement and non-invasive implants. This patient
received no additional treatment, recurred with metastatic
LGSC 13 years later and died of disease 15 years post-
diagnosis. The tumor was found to have a KRAS hotspot
mutation (chr12:25,398,285C >G, G12R) at a similar allelic
fraction in the primary (SBT, 57%) and recurrent (LGSC,
44%) sample by both Ion Torrent and MiSeq.
Mutational stability over space and time
Multiple samplings from both the primary and recurrent
setting from three cases (LGSC-9, LGSC-10 and LGSC-12)
were used to assess the spatial and temporal stability of
features (see Figure 2C-E for overview of clinical course).
LGSC-9 is from a 51 year old patient diagnosed
with stage IIIB SBT of the right ovary with non-
invasive implants. No additional treatment was given
after primary surgery. More than 8 years (100 months)
following initial diagnosis, there was tumor recurrence
involving the ovary and rectosigmoid, demonstrating ma-
lignant transformation to LGSC with borderline features.
This was treated by complete surgical resection. A second
recurrence (sigmoid mass) of LGSC occurred 23 months
later. At this time she was treated with anastrozole (a non-
steroidal aromatase-inhibitor [28]), and died of disease
141 months following initial diagnosis. Sequencing ana-
lysis revealed a somatic, non-synonymous mutation in
NRAS (chr1:115,256,529 T > C, Q61R) at a comparable










torrent and MiSeq. The presence of a specific mutation (listed on left)
the corresponding position, with the shade of the box reflecting the
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Figure 2 Overview of clinical course for patients with true positive mutations. The clinical course for LGSC-3 (A), LGSC-11 (B), LGSC-9 (C),
LGSC-12 (D) and LGSC-10 (E) are shown, with treatment at each step displayed on the left and time indicated on the right.
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the original SBT and 3 from the first recurrence of
LGSC (2 from rectosigmoid and 1 from the left pelvic
sidewall). The same mutation was also observed at a
lower fraction (5%) in a fresh ctDNA sample obtained
following the second recurrence. The stability of this
mutation among all 7 samples was confirmed by digital
PCR (Figure 3/Additional file 20).
LGSC-12 is from a patient diagnosed with stage IIB
LGSC at the age of 57. Her disease was distributed
throughout the pelvis with implants on the rectosigmoid
colon. Following diagnosis, this patient was treated with
etoposide (topoisomerase inhibitor), tamoxifen (estro-
gen receptor inhibitor) and anastrozole (non-steroidal
aromatase inhibitor), before recurring 18 months later
with LGSC involving the abdominal wall. She died of
disease 53 months following her original LGSC diagno-
sis. Of note, this patient had a documented history ofSBT 36 years prior to her diagnosis with LGSC; however
tissue samples were not available for analysis. Sequen-
cing of 4 primary LGSC samples (including 2 from the
pelvic tumor, 1 from the rectosigmoid tumor and 1 from
a peri-aortic tumor nodule) and 2 recurrent LGSC
samples (both from the abdominal wall tumor) revealed
somatic non-synonymous mutations in both BRAF
(chr7:140,453,136A > T, V600E) and SMAD4 (chr18:48,
591,918C >G, R361G). Both of these mutations had an
allelic fraction of 31-55% in all samples (BRAF median
51%, range 37-55%; SMAD4 median 49%, range 31-51%),
suggesting that they were both stable over space and
time (see Additional file 19 for confirmation by Sanger in
select samples).
LGSC-10 is from a patient diagnosed with bilateral
ovarian LGSC with extensive extra-ovarian involvement
(stage IV) at the age of 57. Adjuvant treatment included
6 cycles of carboplatin/paclitaxel, radiation, anastrozole
Figure 3 Stability of nras q61r mutation in multiple tumor samplings over space and time and circulating tumor DNA. Detection of the
NRAS Q61R mutation in tumor samples from the original SBT (Sample 9P1-9P3, top panels) and first LGSC recurrence (Sample 9R1-9R3, middle
panels) by the Raindance Raindrop digital PCR assay are shown. Mutation status was also determined in the ctDNA sample obtained following
the second LGSC recurrence (Sample 9CTDNA), corresponding normal (Sample 9 N) and non template control (NTC) (bottom panels). The wild
type (‘WT’) and mutant (‘MUT’) population are circled in each panel, with the % MUT indicated in the top right corner (MUT drops/total of
WT + MUT droplets). Consistent with Ion Torrent and MiSeq, the NRAS Q61R mutation was observed in all 6 tumor samples and the ctDNA
sample, and was not detected in the corresponding normal.
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later at which point she was treated with radiation,
liposomal doxorubicin chemotherapy and gemcitabinebefore dying of her disease 62 months following initial
diagnosis. Unlike cases LGSC-9 and LGSC-12, sequencing
of 4 primary and 4 recurrent samples revealed extensive
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(and Additional file 20), 2 of 4 specimens from the
primary setting, both from the right ovary, contained
a KRAS G12V hotspot mutation (22-31% allele fraction),
while the specimen from the left ovary contained aFigure 4 Instability of KRAS G12V AND BRAF G469V mutations over b
confirm KRAS and BRAF mutation status in all 8 tumor samples and the cor
(Sample 10P1-10P4) shown on the left and a representative sample from th
(Sample 10 N) shown on the right. The relative location of each sample in
surgery colored in green and those from the recurrent surgery colored in o
wild type (‘WT’) and mutant (‘MUT’) population are circled in each panel, w
WT +MUT droplets). The KRAS G12V mutation was detected in Samples 10
in Sample 10P3. All remaining samples were negative for KRAS G12V, BRAFlow level (3-7%) BRAF mutation (chr7:140,481,402C >
A, G469V). Neither of these mutations were detected in
the remaining specimen from the primary surgery (vaginal
septal tumor) or any of the recurrent samples (including 3
from a right lower quadrant subcutaneous nodule and 1oth space and time. Raindance Raindrop digital PCR was used to
responding normal, with the four samples from the primary surgery
e recurrent surgery (Sample 10R1) and the corresponding normal
the patient is shown in the bottom right, with those from the primary
range (courtesy of Vicky Earle, UBC graphics). Similar to Figure 3, the
ith the % MUT indicated in the top right corner (MUT drops/total of
P1 and 10P2, while the BRAF G469V mutation was exclusively detected
G469V and NRAS Q61R (not shown).
Tone et al. BMC Cancer 2014, 14:982 Page 8 of 13
http://www.biomedcentral.com/1471-2407/14/982from an umbilical margin large nodule). This was not
a reflection of tumor purity, as all mutation-negative
specimens had comparable tumor cellularity by histo-
pathologic assessment (80-95%) and identical allele
fractions of common SNPs in FGFR3 and PDGFRA
(≥99%, data not shown).
Overall trends in mutational stability
As shown in Table 2, four of five cases with true positive
mutations were stable over time and/or space, including
two cases that originally presented as SBT and recurred
as an invasive LGSC. In contrast, one case showed
instability of KRAS and BRAF over both space and
time. Overall, mutations in NRAS and SMAD4 were
stable in one case each, while genes mutated in more than
one study case (KRAS and BRAF) showed different
patterns of stability/instability for distinct variants
(BRAF V600E vs. G469V, KRAS G12R vs. G12V) and
even for the same variant (KRAS G12V).
Discussion
Among the 11 cases of LGSC sequenced in our study,
only 7 confirmed somatic mutations were identified in
5 cases from a targeted hotspot panel of 46 cancer-
associated genes. This low mutation rate is consistent
with the detection of only 10 mutations per tumor by
exome sequencing by Jones et al. [10], and further
suggests that few mutational events are required to
achieve malignancy. The frequency of mutations in
LGSC is much lower than in other subtypes of ovarian
carcinoma such as HGSC (n = 61 mutations/tumor by
exome sequencing) [29] and clear cell carcinoma (n = 34
mutations/tumor by exome sequencing) [30]. This likely
suggests that: [1] there is limited replication of precursor
cells prior to initiation of tumorigenesis, [2] there are few
bottlenecks once initiation occurs, and [3] the ratio of
driver to passenger mutations should be higher than in
other tumor types [10]. Consequently, targeted agentsTable 2 Overall trends in stability over time and space for
confirmed somatic mutations in LGSC*
Time Time and Space




KRAS G12V Stable Unstable
NRAS Q61R Stable
SMAD47 R361G Stable
*Only those mutations observed by two independent technologies
(true positives) included.
Note: not all cases included in table as no confirmed somatic mutations in
LGSC-2, −4, −5 or −13; mutations in LGSC-6 and −8 only observed by either
Ion Torrent or MiSeq.would likely be particularly effective in women with LGSC
if key mutations are shown to be stable.
The most commonly reported drivers in LGSC are
KRAS and BRAF. We detected a KRAS mutation in
three patients (including two stage IIIC and one stage
IV) and a BRAF mutation in two patients (including one
stage IIB and one stage IV). Previous studies have
reported conflicting findings with respect to mutation of
KRAS/BRAF and disease stage, with the Jones study [10]
detecting KRAS or BRAF mutations in 4/13 (31%) and
3/13 (23%) of stage III LGSC patients respectively.
Additional studies report BRAF mutations in only 3%
[12] and 5% [13] of advanced stage LGSC. Grisham
and Wong both reported that women with mutations
in KRAS and/or BRAF [12,13] experience a more favorable
outcome than women without these mutations. This posi-
tive prognostic effect appears to be dominated by BRAF
V600E mutations, with a lower incidence of stage III-IV
disease, enrichment for SBT rather than invasive LGSC
and reduced requirement for systemic treatment among
women with this mutation [12,13]. Possible explanations
include reports that SBTs from women with BRAF
mutations over-express genes with cell growth inhibitory
effects [12] or that activating BRAF mutations induce
cellular senescence and prevent progression to LGSC
[12,31-33]. In our study we observed a trend for increased
mean overall survival in study patients with a MAPK
pathway mutation (KRAS, BRAF, NRAS) compared to
patients with wildtype status (92 months vs. 60 months
respectively; p = 0.23); however, this difference in out-
come was largely influenced by the two cases originally
presenting as a SBT (143 and 183 months) and disappeared
when these cases were excluded from the analysis.
The mutational status of NRAS, member of the MAPK
pathway, showed stability over multiple different tumor
sites and over a span of 8 years between original diagnosis
with SBT and recurrence with an invasive LGSC (case
LGSC-9). The presence of this stable feature at a low level
in plasma ctDNA, obtained following a second recurrence
of LGSC, also clearly highlights the potential utility of
this source for disease monitoring (i.e. tumor response,
persistence or recurrence).
SMAD4 mutational status in case LGSC-12 was also
consistent among 6 tumor samples from 4 different sites
in the primary and recurrence, and despite multiple
treatment cycles. Although found to be unstable in
another case, all samples from LGSC-12 also contained a
BRAF mutation at a similar allelic fraction. The observed
SMAD4 mutation (chr18:48,591,918C >G, R361G) is at a
highly conserved genomic position among placental
mammals, and is situated within the C-terminus MH2
domain of the SMAD4 protein. This domain mediates
protein-protein interactions and provides functional
specificity and selectivity. It was previously reported
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in human tumors, with a mutational hotspot corresponding
to codons 330–370 [34]. Lassus et al. reported allelic loss at
one or more loci at 18q12.3-q23 in 59% of ovarian serous
carcinomas (or 7.1% of grade 1 tumors), with lost or
weak expression of SMAD4 protein in a subset of
these tumors [35]. Mutations in SMAD4 have been
reported to frequently co-exist with KRAS mutations
in colorectal cancer [36], and studies in pancreatic
cancer suggest that wildtype SMAD4 blocks progression
of KRAS G12D-initiated tumors [37]. In addition,
mutation of KRAS, NRAS and BRAF [38-46], and loss
of functional SMAD4 [47], have all been reported to
predict resistance to anti-EGFR therapy. Unfortunately we
were unable to assess the impact of the SMAD4 R361G
mutation on protein expression by IHC in our samples,
therefore we cannot comment on the utility of SMAD4
mutation status as a predictive marker in women with
LGSC without further study.
In contrast to NRAS and SMAD4, mutations in KRAS
and BRAF were not stable in one patient (LGSC-10) in
our study, despite traditionally being thought of as
‘drivers’ of tumorigenesis. This is akin to our recent
observation that mutations in other key ‘drivers’ PIK3CA
and CTNNB1 are only present in a subset of ovarian
HGSC samples from the same patient [48]. These examples
clearly defy the concept of oncogene addiction, which
posits that the growth and survival of a tumor is dependent
on a single dominant oncogene [49,50]. Our findings in
LGSC-10 suggest that even at the time of primary
diagnosis three distinct tumors/clones were present
(i.e. KRAS-mutation positive, BRAF-mutation positive and
KRAS/BRAF-mutation negative). As neither KRAS nor
BRAF were mutated in any of the recurrent samples, a
different, as yet unidentified, dominant gene or pathway
in the KRAS/BRAF-negative population was likely driving
disease recurrence. One possibility is that we have missed
a mutation in gene/s either directly or indirectly involved
in the MAPK pathway that is not included on the targeted
panel used to screen our samples. The KRAS and BRAF
mutations were detected at an allelic fraction of 22-31% in
the right ovary and 3-7% in the left ovary respectively,
hence the clonal population containing an undetected
driver mutation could have already been present in some
or all of the tumor samples at primary debulking; expan-
sion/recurrence of this population could then explain the
absence of mutant KRAS/BRAF in the recurrent set-
ting. In addition, mutations such as those in KRAS
and BRAF that occur early in the development of SBT/
LGSC [17] may not be required and/or advantageous for
tumor maintenance once additional alterations are ac-
quired. This phenomenon has previously been described
in HGSC, in which secondary mutations in BRCA1/2
restore protein function and result in acquired resistanceto treatment [51]; however, reversion of both a KRAS
and BRAF mutation in the current scenario seems
highly unlikely.
Of potential interest, LGSC-10 was the only study case
diagnosed with stage IV disease and the only patient
treated with radiation after primary diagnosis. While the
presence of mutational instability in the primary setting
(prior to treatment) argues against a direct impact of
radiation, the possibility of instability exclusively in stage
IV LGSC is an intriguing one that requires more study.
To date, limited studies have reported on either temporal
or spatial instability of BRAF/KRAS mutations in SBT and
LGSC. Instability in KRAS mutation status was recently
described in a subset of matched SBT-LGSC pairs
(2/5 cases discordant) [52] and matched SBT-peritoneal
implant pairs (3/37 discordant for KRAS, while 14/14 con-
cordant for BRAF) [53]. A recent study by Heublein et al.
[54] also noted instability in KRAS and BRAF in 2/5 cases
of bilateral SBT. In one case, a KRAS G12V mutation
was detected in one ovary and a BRAF V600E mutation
was detected in the contralateral ovary, while the other
case contained a KRAS G12V and BRAF V600E mutation
in one ovary and only a KRAS G12V mutation in the other
ovary. This is consistent with our finding of spatial hetero-
geneity in the primary setting in LGSC-10. Unfortunately,
a detailed breakdown of disease stage in cases with dis-
cordant vs. concordant sample pairs was not provided in
any of these studies. Instability in KRAS has also been de-
scribed for metastatic colorectal cancer [55,56]. Bossard
et al. [55] reported several patterns of heterogeneity in
KRAS mutation status in 22% of 18 colorectal carcin-
omas studied. This included exclusive presence in the
primary tumor or metastatic site, presence in some
metastases but not others, varied status among differ-
ent samplings from the same metastatic site, and
presence in the recurrent but not primary setting.
Similarly, Otsuka et al. [56] reported the presence of a
KRAS mutation in metastatic sites but not the primary
colorectal tumor in 1 of 9 patients studied; BRAF
mutation status was concordant in all cases, in contrast to
what we observed.
Our finding that mutations in genes such as KRAS or
BRAF are not necessarily stable features could provide
an alternative explanation, in some patients, for the lack
of correlation between response to selumetinib and
KRAS/BRAF mutation status observed by Farley et al.
[18]. Targeted sequencing (i.e. codon 599 of BRAF and
codons 12 and 13 of KRAS) using a single representative
tumor sample from 34/52 (65%) patients revealed a
BRAF and KRAS mutation in 2 (6%) and 14 (41%) cases
respectively. A similar proportion of mutation positive
vs. negative cases responded to selumetinib treatment,
leading the authors to postulate that its activity may
not depend on BRAF/KRAS mutational activation. Tissue
Tone et al. BMC Cancer 2014, 14:982 Page 10 of 13
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tumor in 82% of sequenced cases, metastatic tumor in 6%
and recurrent or persistent tumor in 12% of cases. It is
therefore possible that targetable mutations detected in the
primary tumor were not present in the metastatic or recur-
rent tumor, or vice versa, leading to altered treatment
response. It is also possible that some of these patients had
undetected mutations in NRAS, a stable feature in our
study, which also predicts response to MEK inhibitors.
It is important to recognize the limitations of our
study, most notably small sample size and use of a hot-
spot targeted gene panel. Firstly, the small number of
cases used in this study (despite being a collaboration
between three institutions) is illustrative of the challenge
in identifying primary-recurrent pairs for a rare tumor
type such as LGSC. Confirmation of our findings in a
larger cohort of LGSC will therefore require participa-
tion by multiple institutions or establishment of a world-
wide registry. Secondly, by limiting the sequencing
discovery phase to a panel of hotspot mutations in 46
genes, it is highly likely that we have missed additional
case-specific mutations in our study population. How-
ever, a closer look at the mutations discovered by Jones
et al. through exome sequencing [10] revealed that only
KRAS and BRAF were recurrently mutated in LGSC.
This suggests that it is also unlikely that we have missed
additional recurrent drivers of disease, although patient-
specific drivers outside the normal patterns of LGSC
may exist. Thirdly, we have not investigated potential al-
ternative drivers of disease that may be important in
cases without identified somatic mutations, such as copy
number alterations, epigenetic changes or microRNAs.
Singer et al. [57] previously reported a progressive in-
crease in copy number alterations from SBT through to
LGSC, most notably allelic imbalance of chromosomes
1p, 5q, 8p, 18q and 22q. This was confirmed by Kuo
et al. [58] who reported an increased chromosomal in-
stability index in LGSC relative to SBT, suggesting that
amplifications, deletions and aneuploidy play a role in
the malignant transformation of SBT. Hemizygous dele-
tion of chromosome 1p36 was especially enriched in
LGSC samples; this region contains the microRNA miR-
34a, which was found to have an anti-proliferative and
pro-apoptotic effect in an LGSC cell line [58]. Finally,
several groups have reported on differential methylation
patterns in SBT and LGSC [59-61], suggesting that
methylation-induced transcriptional silencing of tumor
suppressor genes may play an undefined role in malig-
nant transformation and progression and response to
systemic or targeted therapy.
Conclusions
The extent of intratumoral heterogeneity in kidney,
breast, leukemia and ovarian cancers has recently beendescribed [48,62-64]. Most papers have focused on high-
grade cancers with many somatic mutations, and most
of the mutations described have no immediate clinical
relevance. Herein we show that, in a cancer type known
to have a sparse mutational landscape [10], heterogen-
eity in targetable mutations can be observed. While the
vast majority of evaluable cases contained mutations that
were detected in all samples, one case showed remark-
able instability in hotspot mutations of presumed drivers
of disease, despite not receiving treatment that could
have driven the specific evolution of (KRAS/BRAF) mu-
tant clones. In addition, as we looked within a limited
mutational space, the possibility remains that more
underlying heterogeneity may be revealed in more cases
with further study. Investigation of additional cases is re-
quired to confirm whether a consistent minority of
LGSC cases show clinically relevant mutational hetero-
geneity; this would necessitate a change in clinical trial
design with contemporary samplings of a cancer re-
quired to guide treatment decisions. Alternatively, if not
found to be a general phenomenon upon further study,
confirmation of mutational status in a single sample
would be sufficient.Additional files
Additional file 1: “Additional Information on Study Samples”.
Provides more detailed information on pathologic diagnosis, DNA
quantity and estimated cellularity.
Additional file 2: “LGSC-2 Case Images”. LGSC-2 is from a patient
diagnosed with bilateral ovarian LGSC (stage IIIC) at 57 years old
(LGSC-2-P, top) and metastatic LGSC 46 months after primary diagnosis
(LGSC-2-R, bottom; both 20X).
Additional file 3: “LGSC-3 Case Images”. LGSC-3 is from a patient
diagnosed with bilateral ovarian LGSC (stage IIIC) at 51 years old
(LGSC-3-P, top), and recurrent LGSC 17 months later (LGSC-3-R,
bottom; both 20X).
Additional file 4: “LGSC-4 Case Images”. LGSC-4 is from a patient
diagnosed with ovarian LGSC (IIIB) at the age of 66 (LGSC-4-P), followed
by two separate recurrences 25 months (LGSC-4-R1) and 45 months
(LGSC-4-R2) later (all 20X).
Additional file 5: “LGSC-5 Case Images”. LGSC-5 is from a patient
diagnosed with LGSC (stage IIIC) at age 51 (LGSC-5-P, top) and recurrent
LGSC 37 months later (LGSC-5-R, bottom; both images 100X).
Additional file 6: “LGSC-6 Case Images”. LGSC-6 is from a patient
diagnosed with LGSC (stage IIIC) at 41 years old (LGSC-6-P, top) and
recurrent LGSC 24 months later (LGSC-6-R, bottom; both images 100X).
Additional file 7: “LGSC-8 Case Images”. LGSC-8 is from a patient
diagnosed with metastatic LGSC (stage IIIC) at the age of 33 (LGSC-8-P,
top), with disease recurrence 7 months later (LGSC-8-R, bottom; both
images 100X).
Additional file 8: “LGSC-9 Case Images”. LGSC-9 is from a patient
diagnosed with a serous borderline tumor (stage IIIB) at age 51 (LGSC-9-P1,
LGSC-9-P2, LGSC-9-R3 shown in left panels). This patient received no
additional treatment after surgical resection and recurred with LGSC
100 months later (LGSC-9-R1, LGSC-9-R2, LGSC-9-R3 shown in right
panels; all images 20X).
Additional file 9: “LGSC-10 Case Images”. LGSC-10 is from a patient
diagnosed with bilateral ovarian LGSC (stage IV) at the age of 57
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http://www.biomedcentral.com/1471-2407/14/982(LGSC-10-P1, LGSC-10-P2, LGSC-10-P3, LGSC-10-P4 shown in left panels),
followed by disease recurrence 45 months later (LGSC-10-R1, LGSC-10-R2,
LGSC-10-R3, LGSC-10-R4 shown in right panels; all images at 20X).
Additional file 10: “LGSC-11 Case Images”. LGSC-11 is from a patient
diagnosed with a serous borderline tumor (stage IIIC) at 62 years
(LGSC-11-P, top) followed by recurrence with LGSC 13 years later
(LGSC-11-R, bottom; both images at 20X).
Additional file 11: “LGSC-12 Case Images”. LGSC-12 is from a patient
diagnosed with LGSC (stage IIB) at the age of 57 (LGSC-12-P1, LGSC-12-P2,
LGSC-12-P3, LGSC-12-P4 are shown). This patient was treated with etoposide,
tamoxifen and anastrozole prior to recurrence with LGSC 18 months later
(LGSC-12-R1, LGSC-12-R2 are shown; all images at 20X).
Additional file 12: “LGSC-13 Case Images”. LGSC-13 is from a patient
diagnosed with LGSC (stage IIIB) at the age of 58 (LGSC-13-P, top),
followed by recurrence with LGSC 46 months later (LGSC-13-R, bottom;
both images 20X).
Additional file 13: “Supplemental Methods”. Describes additional
methodological details for DNA extraction, sequencing and digital PCR.
Additional file 14: “Genes/Mutations on Ion Torrent AmpliSeq
panel v1”. Lists genes and hot spot mutations included on the Ion
Torrent AmpliSeq panel.
Additional file 15: “Primer sequences for Sanger sequencing”. Lists
primer sequences used for validation of mutations by Sanger sequencing.
Additional file 16: “Primer sequences for digital PCR”. Lists primer
sequences used for validation of mutations by digital PCR.
Additional file 17: “Allele fraction of confirmed somatic mutations
by Ion Torrent and MiSeq”. The presence of a specific mutation (listed on
left) in a specific tumor sample (listed at bottom) is indicated by a colored
box in the corresponding position, with the shade of the box reflecting the
allelic fraction as detected by (A) Ion Torrent or (B) MiSeq. Corresponding
normal samples were all negative for the described mutations.
Additional file 18: “Ion Torrent and MiSeq reads for true positive
mutations”. Lists the variant reads, total reads and variant frequency by
sample for both Ion Torrent and MiSeq.
Additional file 19: “Stable KRAS, BRAF and SMAD4 mutations in
cases 3 and 12 by Sanger sequencing”. Detection of the KRAS G12V
mutation by Sanger sequencing in LGSC-3-P (A) and LGSC-3-R (B) are
shown. Sanger sequencing also confirmed the presence of the BRAF
V600E and the SMAD4 R361G mutation in LGSC-12-P1 (C and F respectively)
and LGSC-12-R1 (D and G respectively), but not the corresponding normal
sample LGSC-12-N (E and H respectively).
Additional file 20: “Digital PCR results”. Lists the % mutant and %
wildtype droplets corresponding to the digital PCR results shown in
Figures 3 and 4.
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